Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes
- PMID: 22302016
- PMCID: PMC3297690
- DOI: 10.1158/1055-9965.EPI-11-0741
Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes
Abstract
Background: Genome-wide association studies (GWAS) for epithelial ovarian cancer (EOC), the most lethal gynecologic malignancy, have identified novel susceptibility loci. GWAS for survival after EOC have had more limited success. The association of each single-nucleotide polymorphism (SNP) individually may not be well suited to detect small effects of multiple SNPs, such as those operating within the same biologic pathway. Gene set analysis (GSA) overcomes this limitation by assessing overall evidence for association of a phenotype with all measured variation in a set of genes.
Methods: To determine gene sets associated with EOC overall survival, we conducted GSA using data from two large GWAS (N cases = 2,813, N deaths = 1,116), with a novel Principal Component-Gamma GSA method. Analysis was completed for all cases and then separately for high-grade serous histologic subtype.
Results: Analysis of the high-grade serous subjects resulted in 43 gene sets with P < 0.005 (1.7%); of these, 21 gene sets had P < 0.10 in both GWAS, including intracellular signaling pathway (P = 7.3 × 10(-5)) and macrolide binding (P = 6.2 × 10(-4)) gene sets. The top gene sets in analysis of all cases were meiotic mismatch repair (P = 6.3 × 10(-4)) and macrolide binding (P = 1.0 × 10(-3)). Of 18 gene sets with P < 0.005 (0.7%), eight had P < 0.10 in both GWAS.
Conclusion: This research detected novel gene sets associated with EOC survival.
Impact: Novel gene sets associated with EOC survival might lead to new insights and avenues for development of novel therapies for EOC and pharmacogenomic studies.
©2012 AACR.
Conflict of interest statement
The authors have no conflict of interest to declare.
Figures
References
-
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. - PubMed
-
- Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 2003;189:1120–7. - PubMed
-
- McGuire V, Jesser CA, Whittemore AS. Survival among U. S. women with invasive epithelial ovarian cancer. Gynecol Oncol. 2002;84:399–403. - PubMed
-
- Hoskins PJ, O’Reilly SE, Swenerton KD, Spinelli JJ, Fairey RN, Benedet JL. Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. J Clin Oncol. 1992;10:1561–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R21 CA140879/CA/NCI NIH HHS/United States
- CA148112/CA/NCI NIH HHS/United States
- CA140879/CA/NCI NIH HHS/United States
- R01 CA122443/CA/NCI NIH HHS/United States
- CA136393/CA/NCI NIH HHS/United States
- U19 CA148112/CA/NCI NIH HHS/United States
- CA122443/CA/NCI NIH HHS/United States
- P50 CA136393/CA/NCI NIH HHS/United States
- R01 CA114343/CA/NCI NIH HHS/United States
- 10124/CRUK_/Cancer Research UK/United Kingdom
- R01 CA106414/CA/NCI NIH HHS/United States
- GM86689/GM/NIGMS NIH HHS/United States
- C490/A10119/CRUK_/Cancer Research UK/United Kingdom
- A10119/CRUK_/Cancer Research UK/United Kingdom
- CA114343/CA/NCI NIH HHS/United States
- R21 GM086689/GM/NIGMS NIH HHS/United States
- 10119/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Medical
